Skip to main content
SpringerLink
Log in

Palbociclib plus endocrine therapy: no cumulative risks of AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. hormone receptor-positive/human epidermal growth factor receptor 2-negative

Reference

  • Dieras V, et al. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. Journal of the National Cancer Institute : 18 Jul 2018. Available from: URL: http://doi.org/10.1093/jnci/djy109

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Palbociclib plus endocrine therapy: no cumulative risks of AEs. Reactions Weekly 1714, 9 (2018). https://doi.org/10.1007/s40278-018-50189-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-50189-2

Search

Navigation